Learn More About Our Innovative Biotechnology

Press Releases

Full Enrollment of First Cohort of Relapsed/Refractory Non-Hodgkin’s Lymphoma Patients dosed with AVM0703

Publications

AVM Biotechnology – The Platform Therapy for Immune Modulation

Publications

Pharma’s Almanac Features AVM0703

Press Releases

AVM Biotechnology CEO/CSO Selected to Speak at ESWI Conference in Novel and Outstanding Discoveries Track

Videos

What is AVM0703? Find Out!

Press Releases

President Receives Dexamethasone Treatment

Press Releases

AVM Receives FDA Permission for Clinical Trials in COVID-19/ARDS

Press Releases

AVM Expands Executive Team, Appoints Janet R. Rea COO

Videos

Amplifying Scientific Innovation Podcast

Press Releases

AVM’s Dexamethasone Formulation Has Potential For Greater Impact Than Oxford’s

Videos

Oxford/AVM’s potential COVID-19 Treatment Featured on KOMO News

Press Releases

AVM Awarded SBIR Grant From National Cancer Institute

Press Releases

FDA Approves AVM0703 Clinical Trials in R/R Non-Hodgkins Lymphoma

Videos

Cavendish Global 2020

Publications

AVM0703, a New Treatment Option for Lymphoma Patients